
Enteric-coated proteolytic enzyme tablets | Pharmaceutical supply and export enquiries
Each enteric-coated tablet contains: Serratiopeptidase 5 mg, equivalent to 10,000 serratiopeptidase activity units, as stated in the supplied product brief. Activity units should be confirmed against the approved label and analytical method.
Therapeutic class: Proteolytic enzyme / anti-inflammatory adjunct (not an NSAID).
SKU: Serratiopeptidase Tablets
Categories: Pharmaceutical Exporter India · Pharmaceutical Formulations India · WHO GMP Certified Formulations
Serratiopeptidase Tablets (10,000 Units) is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Serratiopeptidase (serrapeptase) is a proteolytic enzyme marketed in some countries for inflammation and swelling. This product brief specifies an enteric-coated 5 mg tablet with 10,000 activity units. Evidence for many claimed benefits is limited or inconsistent, and indications depend on the relevant country’s approval. Healthy Life Pharma Pvt. Ltd. and Healthy Inc are identified in the supplied brief as manufacturer and exporter; verify authorisations and certification before publication.
| Product name | Serratiopeptidase Tablets |
|---|---|
| Confirmed strength | 5 mg |
| Enzyme activity | 10,000 serratiopeptidase units (supplied label claim) |
| Dosage form | Enteric-coated tablet |
| Therapeutic category | Proteolytic enzyme / anti-inflammatory adjunct |
| SKU | Serratiopeptidase Tablets |
| Other strengths | 10 mg and 20 mg mentioned in marketing text; availability and units not confirmed |
| Packaging / shelf life | To be confirmed from approved specifications |
As a protein enzyme, serratiopeptidase may lose activity under unsuitable heat, humidity or acidic conditions. Enteric coating is designed to protect the tablet during passage through the stomach. Key manufacturing considerations include coating integrity, consistent enzyme activity, content uniformity and stability. Specific equipment, coating polymers, process conditions and plant capabilities require verification.
Relevant tests may include identity, proteolytic enzyme activity, dosage uniformity, enteric-coating resistance in acidic media, disintegration or dissolution at intestinal pH, microbial limits and stability. Test limits must match the approved monograph or registered specification; generic numerical limits should not be assumed.
Serratiopeptidase has been studied as an adjunct for postoperative swelling and some inflammatory conditions. However, high-quality evidence is insufficient to establish reliable benefit for many advertised conditions, including osteoarthritis, rheumatoid arthritis, osteoporosis, fibromyalgia, carpal tunnel syndrome, migraine and chronic back pain. It is not an NSAID, not an established treatment for osteoporosis, and should not replace evidence-based care. Use only for locally approved indications on professional advice.
For export enquiries, request the current manufacturing licence, product registration, GMP documentation, certificates of analysis, stability data, packaging specifications and permitted therapeutic claims for the destination market. WHO-GMP status, Star Export House status, CTD/ACTD dossiers, COPP and FSC availability must be confirmed with supporting documents.
5 mg with a stated activity of 10,000 serratiopeptidase units per enteric-coated tablet.
No. It is a proteolytic enzyme; its evidence base and safety profile differ from conventional anti-inflammatory drugs.
Do not crush or split an enteric-coated tablet unless the approved product instructions specifically permit it.
Clinical evidence is insufficient to recommend it as an established treatment for these conditions.
Use only according to the locally approved product label and a qualified prescriber’s instructions. Dosing varies across products and enzyme-activity standards; do not infer a regimen from the tablet weight alone. Swallow the enteric-coated tablet intact. Follow the specific label’s food-related instructions rather than assuming all formulations must be taken on an empty stomach.
Reported effects include gastrointestinal upset and allergic reactions. There are concerns about possible bleeding interactions, especially with anticoagulants or antiplatelet medicines; discuss use with a clinician before surgery or if you have a bleeding disorder. Safety in pregnancy, breastfeeding and children is not well established. Stop use and seek medical care for serious rash, breathing difficulty or unusual bleeding.
Keep in the original moisture-protective packaging, away from excess heat and humidity and out of reach of children. Use the approved label for the precise storage temperature and expiry date; the stated 24–36 month shelf life is not independently confirmed.
For B2B and professional reference only. Product strength and claims are taken from the supplied brief; manufacturing credentials, regulatory status and approved indications require documentary verification.